Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653749 | 1.00 | F2 (0.40) | F2L3MBTL1MAPTPOLBMAPK1 | |
| SCHEMBL14131859 | 0.81 | MAPT (0.50) | L3MBTL1MAPTPOLBMAPK1SYK | |
| SCHEMBL6653753 | 0.80 | F2 (0.42) | F2L3MBTL1MAPTKMT2ASLC6A2 | |
| SCHEMBL6653750 | 0.78 | F2 (0.37) | F2L3MBTL1MAPTSYKKMT2A | |
| SCHEMBL7408405 | 0.77 | ITGB3 (0.53) | MAPTPOLBMAPK1 | |
| SCHEMBL8303000 | 0.77 | LMNA (0.50) | L3MBTL1MAPTPOLBMAPK1SYK | |
| SCHEMBL21924239 | 0.75 | KMT2A (0.41) | MAPTMAPK1SYKKMT2AMEN1 | |
| SCHEMBL6653024 | 0.75 | KMT2A (0.48) | F2L3MBTL1MAPTPOLBMAPK1 | |
| SCHEMBL6653550 | 0.73 | KMT2A (0.50) | F2L3MBTL1MAPTPOLBMAPK1 | |
| SCHEMBL7412932 | 0.72 | ITGB3 (0.42) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070049-B1 | BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-06-30 | — | — | EP | disclosed |
| US-6344486-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | disclosed |
| US-20010031870-A1 | Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors | SOLL RICHARD M (US) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031870-A1 | Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors | PLG, F9, TFPI | F2 18/4885L3MBTL1 1362/4885MAPT 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.